GlassScriptPhysician profile
Radha Patel
NPI 1326793910
$6,854.49
in general payments reported to CMS, 2019-2025
60 companies · none reported in 2025
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $191 · 2023: $3,454 · 2024: $3,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,960 · Education: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,959.65 |
| Education | $703.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $438.77 | 2022-2024 | Pemazyre, Monjuvi, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $411.71 | 2023-2024 | |
| Pfizer INC. | $362.14 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $344.74 | 2023-2024 | Keytruda, Welireg, Reblozyl |
| Janssen Biotech, INC. | $317.53 | 2023-2024 | Imbruvica, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $309.56 | 2023-2024 | Enhertu, Lynparza, Tagrisso |
| Celgene Corporation | $272.43 | 2023-2024 | Reblozyl, Pomalyst, Opdualag |
| Exelixis INC. | $261.91 | 2023-2024 | Cabometyx |
| Gilead Sciences, INC. | $258.96 | 2023-2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $258.63 | 2023-2024 | Fruzaqla, Alunbrig, Iclusig |
| Daiichi Sankyo INC. | $246.03 | 2023-2024 | Enhertu |
| Karyopharm Therapeutics INC. | $175.25 | 2023-2024 | Xpovio |
| Genzyme Corporation | $172.28 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $160.74 | 2022-2024 | Opdivo, Opdualag |
| Taiho Oncology, INC. | $156.84 | 2023-2024 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $154.55 | 2023-2024 | |
| Astellas Pharma US INC | $152.45 | 2023-2024 | Xtandi |
| Array Biopharma INC | $145.35 | 2023-2024 | Mektovi, Braftovi, Xalkori |
| Puma Biotechnology, INC. | $133.55 | 2023-2024 | |
| Stemline Therapeutics INC. | $118.23 | 2023-2024 | Orserdu |
| Lilly USA, LLC | $117.53 | 2023-2024 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $101.97 | 2024 | Libtayo |
| Cti Biopharma Corp. | $98.50 | 2023 | Vonjo |
| Amgen INC. | $93.93 | 2023 | Kyprolis, Lumakras, Blincyto |
| Blueprint Medicines Corporation | $87.05 | 2023-2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $84.99 | 2023 | |
| Beigene USA, INC. | $84.71 | 2023 | Brukinsa |
| Emd Serono, INC. | $84.16 | 2023-2024 | Bavencio |
| Sobi, INC | $83.11 | 2024 | |
| Eisai INC. | $77.73 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.63 | 2023-2024 | Gilotrif |
| Progenics Pharmaceuticals, INC. | $68.45 | 2024 | |
| Genmab U.S., INC. | $62.83 | 2023 | Epkinly |
| Pharmacosmos Therapeutics INC. | $62.40 | 2023-2024 | Cosela, Monoferric |
| Jazz Pharmaceuticals INC. | $55.76 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $52.02 | 2024 | |
| Morphosys, US INC. | $51.82 | 2023-2024 | Monjuvi |
| Genentech USA, INC. | $49.65 | 2024 | Tecentriq, Phesgo, Tecentriq Hybreza |
| Agios Pharmaceuticals, INC. | $44.43 | 2023 | Pyrukynd |
| Pharmaessentia USA Corporation | $42.42 | 2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $40.35 | 2023 | Rezlidhia, Tavalisse |
| Mirati Therapeutics, INC. | $37.83 | 2023 | Krazati |
| Seagen INC. | $33.60 | 2023 | Padcev |
| Abbvie INC. | $33.54 | 2024 | |
| Immunocore Limited | $33.44 | 2024 | Kimmtrak |
| Deciphera Pharmaceuticals INC. | $31.92 | 2023 | Qinlock |
| Glaxosmithkline, LLC. | $31.71 | 2023-2024 | Ojjaara |
| Foundation Medicine, INC. | $30.96 | 2023 | Foundationone Liquid Cdx |
| Sumitomo Pharma America, INC. | $29.32 | 2024 | Orgovyx |
| Adc Therapeutics America, INC. | $28.33 | 2023 | |
| Novocure INC. | $27.52 | 2024 | Optune |
| Alexion Pharmaceuticals, INC. | $27.05 | 2024 | Ultomiris |
| Springworks Therapeutics, INC. | $22.50 | 2024 | Ogsiveo |
| Aveo Pharmaceuticals, INC. | $21.30 | 2024 | |
| G1 Therapeutics, INC. | $21.05 | 2023 | Cosela |
| Immunogen, INC. | $20.41 | 2023 | Elahere |
| Adaptive Biotechnologies Corporation | $20.02 | 2024 | Clonoseq |
| Kyowa Kirin, INC. | $18.15 | 2023 | Poteligeo |
| Catalyst Pharmaceuticals, INC. | $15.62 | 2023 | Firdapse |
| Organon LLC | $6.13 | 2023 | Ontruzant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.